Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Key Highlights
- ➤Nu-8 achieved up to 97% E. coli growth inhibition in rodent UTI models
- ➤Bisphosphocin compounds showed in vivo activity against pulmonary infection models
- ➤Bisphosphocin compounds demonstrated in vitro activity against resistant UTI bacteria
- ➤Nu-3 diabetic foot ulcer Phase 2a topline data expected in first quarter of 2027
Expert Statements
Kelvin Cooper, Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics
“We continue to be encouraged by the performance of different members of the Bisphosphocin(®) class of compounds when tested against various bacterial species, which are known to have a major impact on human health and are key contributors to the AMR crisis.”
Kelvin Cooper, Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics
“The Bisphosphocin(®) class of compounds possesses key characteristics including rapid and potent antimicrobial action and broad-spectrum activity with no expected resistance development, which could make them valuable assets in fighting the AMR crisis.”
Kelvin Cooper, Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics
“We look forward to continuing development of the various Bisphosphocin(®) compounds to identify the most suitable candidate to be advanced into early clinical development.”
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds PR Newswire
Intravesical administration of the Bisphosphocin(®) Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group.
Get started
Create a free account to read the full story.